Anti-p16INK4a Antibody

HUABIO

Anti-p16INK4a Antibody

7

Flow Cytometry, ImmunoFluorescence, Western Blot

WB,IHC-P,IF-Cell,FC

Research Use Only

Polyclonal

1 mg/ml

Unconjugated

CDKN2A

cyclin dependent kinase inhibitor 2A

ARF, CAI2, CDK4I, CDKN2, CMM2, INK4, INK4A, MLM, MTS-1, MTS1, P14, P14ARF, P16, P16-INK4A, P16INK4, P16INK4A, P19, P19ARF, TP16, cyclin-dependent kinase inhibitor 2A, CDK4 inhibitor p16-INK4, CDKN2A/ARF Intron 2 lncRNA, alternative reading frame, cell cycle negative regulator beta, cyclin-dependent kinase 4 inhibitor A, cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4), inhibitor of cdk4 A, multiple tumor suppressor 1, multiple tumour suppressor 1

Rabbit

IgG

Cyclin-dependent kinase inhibitor 2A

CDKN2A, also known as cyclin-dependent kinase inhibitor 2A, is a gene which in humans is located at chromosome 9, band p21.3. It is ubiquitously expressed in many tissues and cell types.The gene codes for two proteins, including the INK4 family member p16 (or p16INK4a) and p14arf. Both act as tumor suppressors by regulating the cell cycle. p16 inhibits cyclin dependent kinases 4 and 6 (CDK4 and CDK6) and thereby activates the retinoblastoma (Rb) family of proteins, which block traversal from G1 to S-phase. p14ARF (known as p19ARF in the mouse) activates the p53 tumor suppressor. Somatic mutations of CDKN2A are common in the majority of human cancers, with estimates that CDKN2A is the second most commonly inactivated gene in cancer after p53. Germline mutations of CDKN2A are associated with familial melanoma, glioblastoma and pancreatic cancer.The CDKN2A gene also contains one of 27 SNPs associated with increased risk of coronary artery disease.

Human, Mouse

Human,Mouse

-20°C,2°C to 8°C

41116161